These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24950979)

  • 21. Preface on application of omics technologies in cancer biology and therapy.
    Georgakilas AG
    Cancer Lett; 2016 Nov; 382(1):A1. PubMed ID: 27765153
    [No Abstract]   [Full Text] [Related]  

  • 22. Mass spectrometry based proteomics and metabolomics in personalized oncology.
    Kowalczyk T; Ciborowski M; Kisluk J; Kretowski A; Barbas C
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165690. PubMed ID: 31962175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brave-ish New World--What's Needed to Make Precision Oncology a Practical Reality.
    MacConaill LE; Lindeman NI; Rollins BJ
    JAMA Oncol; 2015 Oct; 1(7):879-80. PubMed ID: 26181886
    [No Abstract]   [Full Text] [Related]  

  • 24. The era of precision oncogenomics.
    Carpten JC; Mardis ER
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610397
    [No Abstract]   [Full Text] [Related]  

  • 25. Cancer molecular markers: A guide to cancer detection and management.
    Nair M; Sandhu SS; Sharma AK
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):39-55. PubMed ID: 29428478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
    Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Harnessing the potential of reverse-phase protein array technology: Advancing precision oncology strategies.
    Masuda M; Nakagawa R; Kondo T
    Cancer Sci; 2024 May; 115(5):1378-1387. PubMed ID: 38409909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Precision Cancer Medicine 2.0-Oncology in the postgenomic era.
    Masina R; Caldas C
    Mol Oncol; 2024 Sep; 18(9):2065-2069. PubMed ID: 39109701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. European society for medical oncology virtual congress: Molecular analysis for precision oncology, October 9th - October 10th, 2020.
    Messin LJ
    EBioMedicine; 2021 Feb; 64():103219. PubMed ID: 33517074
    [No Abstract]   [Full Text] [Related]  

  • 30. Omics-based molecular classifications empowering in precision oncology.
    Zhou Z; Lin T; Chen S; Zhang G; Xu Y; Zou H; Zhou A; Zhang Y; Weng S; Han X; Liu Z
    Cell Oncol (Dordr); 2024 Jun; 47(3):759-777. PubMed ID: 38294647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New ESMO scale ranks mutations as cancer medicine targets.
    Fricker J
    Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
    [No Abstract]   [Full Text] [Related]  

  • 32. Biomarker testing in cancer management- can one size fit all?
    Sholl LM; Halmos B
    Br J Cancer; 2022 Oct; 127(7):1177-1179. PubMed ID: 36064588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-throughput molecular assays for inclusion in personalised oncology trials - State-of-the-art and beyond.
    Edsjö A; Russnes HG; Lehtiö J; Tamborero D; Hovig E; Stenzinger A; Rosenquist R;
    J Intern Med; 2024 Jun; 295(6):785-803. PubMed ID: 38698538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent Advancements and Innovations in Pediatric Precision Oncology.
    Mangum R; Lin FY; Parsons DW
    J Pediatr Hematol Oncol; 2024 Jul; 46(5):262-271. PubMed ID: 38857189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrating proteomics into precision oncology.
    Wahjudi LW; Bernhardt S; Abnaof K; Horak P; Kreutzfeldt S; Heining C; Borgoni S; Becki C; Berg D; Richter D; Hutter B; Uhrig S; Pfütze K; Leichsenring J; Glimm H; Brors B; von Kalle C; Stenzinger A; Korf U; Fröhling S; Wiemann S
    Int J Cancer; 2021 Mar; 148(6):1438-1451. PubMed ID: 32949162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empowering effective biomarker-driven precision oncology: A call to action.
    Lawler M; Keeling P; Kholmanskikh O; Minnaard W; Moehlig-Zuttermeister H; Normanno N; Philip R; Popp C; Salgado R; Santiago-Walker AE; Trullas A; van Doorn-Khosrovani SBVW; Vart R; Vermeulen J; Vitaloni M; Verweij J
    Eur J Cancer; 2024 Sep; 209():114225. PubMed ID: 39053288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
    Molloy MP; Engel A
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
    [No Abstract]   [Full Text] [Related]  

  • 38. [Precision medicine in oncology].
    Mack E
    Inn Med (Heidelb); 2024 Mar; 65(3):194-201. PubMed ID: 37921995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization of Genomics and Functional Genomics to Inform Clinical Decisions in IR.
    Schachtschneider KM; Gaba RC
    J Vasc Interv Radiol; 2018 Aug; 29(8):1117-1121. PubMed ID: 30055782
    [No Abstract]   [Full Text] [Related]  

  • 40. Using germline genomics to individualize pediatric cancer treatments.
    Pinto N; Cohn SL; Dolan ME
    Clin Cancer Res; 2012 May; 18(10):2791-800. PubMed ID: 22589487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.